Insulet Corporation (NASDAQ: PODD) — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing was signed February 26, 2015. Insulet develops, manufactures and sells the tubeless OmniPod insulin management system, alongside diabetes supplies distributed through its Neighborhood Diabetes business.
Financial performance and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $288.7 million | $247.1 million |
| Gross profit / gross margin | $143.3 million / 49.6% | $112.4 million / 45.5% |
| Operating loss | $12.3 million | $29.1 million |
| Net loss | $51.5 million | $45.0 million |
| Operating cash flow | $8.9 million | $3.3 million |
| Capital expenditures | $11.5 million | $7.3 million |
| Cash and cash equivalents, year-end | $151.2 million | $149.7 million |
| Working capital, year-end | $163.9 million | $155.8 million |
| Long-term debt, net of discount | $169.0 million | $113.7 million |
Revenue increased 17%, principally from continued OmniPod adoption in the U.S. and internationally. International sales were 18% of revenue, compared with 10% in 2013. Gross margin improved as unit costs declined through material savings, supplier volume discounts and greater manufacturing-overhead absorption. Operating loss narrowed, but the net loss widened, primarily because of debt-extinguishment costs. The company remained loss-making, with an accumulated deficit of $578.0 million.
Fourth-quarter 2014 revenue was $72.6 million, gross profit was $36.7 million and net loss was $5.4 million. The comparable fourth-quarter 2013 figures were $68.5 million, $33.0 million and $2.5 million, respectively.
Material changes and unusual items
- In June 2014, Insulet issued $201.3 million of 2% convertible senior notes due 2019 and repurchased approximately $114.9 million principal amount of 3.75% notes. Repurchase, conversion and redemption of the old notes generated a $23.2 million loss on debt extinguishment.
- General and administrative expense included significant executive retirement and transition costs; the filing reports approximately $10.4 million of management-transition expense in accrued-expense disclosures. Stock-based compensation rose to $22.5 million from $12.7 million.
- The company recorded approximately $7.0 million of expense for its June 2014 settlement with Becton, Dickinson and Company, including a one-time payment and legal fees, and entered into a cross-license.
- Neighborhood Diabetes remained unable to provide certain mail-order diabetes testing supplies to Medicare beneficiaries after losing a competitive-bidding contract effective July 1, 2013, reducing revenue in 2014 and expected to continue to affect results.
Outlook, management commentary and risks
Management expected revenue to continue increasing in 2015 as the customer base expanded in the U.S. and abroad and the company pursued pharmaceutical drug-delivery opportunities. It expected research and development and sales and marketing spending to rise in 2015, while general and administrative expense was expected to decline from 2014, partly because of prior-year one-time costs. Management said cash, together with expected product-sale proceeds, should cover projected operating and debt-service requirements for at least the next twelve months. This is management’s expectation, not a guarantee; it also expected near-term net losses while investing in growth.
- Key exposures include dependence on OmniPod sales and reimbursement, continued losses, competition, and the need to improve or sustain manufacturing costs and gross margins.
- Complete OmniPods are manufactured at a single facility in China by a Flextronics subsidiary; Insulet also relies on multiple outside and, in some cases, sole-source component suppliers.
- The $201.3 million notes mature in 2019; the company cited possible need for additional financing and risks relating to debt service, conversion-related dilution and refinancing. Contractual obligations included $203.1 million of long-term debt payments in 2019, including interest.
- In January 2015, Insulet settled a Massachusetts Attorney General matter concerning Neighborhood Diabetes prescription refills and had recorded a $1.5 million liability at year-end 2014. The company also disclosed an ongoing Massachusetts sales-and-use-tax audit and other ordinary-course proceedings; it did not quantify the audit exposure clearly in the provided filing text.
- Other risks include regulatory and product-safety requirements, intellectual-property claims, customer collection risk, international expansion and reliance on distributor and payor relationships. The filing says two customers accounted for 15% and 11% of 2014 revenue, and two customers represented 19% and 10% of gross receivables at year-end.
Ernst & Young issued an unqualified opinion on the financial statements and internal controls; management and the auditor reported effective internal control over financial reporting as of December 31, 2014.
Important facts for investors to verify
- Whether revenue growth and improved gross margin continued, and whether lower unit costs translate into sustainable operating profitability.
- Actual 2015 revenue, expense and cash-flow performance against management’s directional expectations; the filing provides no numerical revenue or earnings guidance.
- Cash generation, working-capital needs, capital spending and the ability to meet debt obligations, especially the 2019 note maturity.
- Effects of Medicare competitive bidding and changes in private-payor coverage, pricing and reimbursement on both OmniPod and Neighborhood Diabetes.
- Manufacturing continuity at the China facility, supplier concentration, product quality and the progress and regulatory status of planned product developments.
- Final costs or developments relating to the Massachusetts tax audit and other legal, regulatory or reimbursement contingencies.